Big Cypress National Preserve

Travel Expert Jennifer Weatherhead Shares Timely Information and Inspiration About Great Getaways for the Holidays on TipsOnTV

Retrieved on: 
Tuesday, December 6, 2022
Golf, Sunlight, Sunshine State, Big Cypress National Preserve, Swimming, Everglades National Park, Space Coast, Travel, Cultural diversity, Kennedy Space Center, Human, Florida Keys, Astronaut, Gift, Lion Country Safari, Hotel, Amusement park, Central Florida, Expedia

Travel expert, Jennifer Weatherhead shares her favorite Florida travel experiences and some amazing deals.

Key Points: 
  • Travel expert, Jennifer Weatherhead shares her favorite Florida travel experiences and some amazing deals.
  • Florida is a great state that offers so many different vacation experiences such as great beaches, theme parks and state and national parks.
  • Whether looking for a romantic getaway, a girl's trip or a family vacation, Florida has something for everyone.
  • VISIT FLORIDA and its partners have teamed up with Expedia to offer up to 25 percent off Florida hotels this holiday season.

Over 90% of National Parks Bounce Back as Pandemic Fears Fade According to ValuePenguin.com Survey

Retrieved on: 
Wednesday, April 13, 2022
Twitter, Independence National Historical Park, Klondike Gold Rush National Historical Park, Research, Boston National Historical Park, National park, NEW, Facebook, City, Big Cypress National Preserve, Risk, LendingTree, Amusement park, Tourism

NEW YORK, April 13, 2022 /PRNewswire/ -- With travel restrictions still in place for many international destinations, along with a desire to avoid or escape dense populations in cities, outdoor itineraries within the U.S. are holding greater appeal as pandemic fears start to fade. 

Key Points: 
  • A recent study by ValuePenguin looked at national park and monument visitation to see which parks saw the most and least visitors, and which ones are on the road to recovery.
  • National parks in 2021 reclaimed 91% of their 2019 pre-pandemic visitation.
  • As pandemic fears faded, national park visitors stayed longer.While visitorship in 2021 was down 9% from 2019, the number of hours spent at national parks was down only 5%.
  • But not all parks fared the same during the early portion of the pandemic.

Abacus Capital, Big Cypress Capital and Stockbridge Sign Birdseye Renewable Energy to Switch Yard in Charlotte; Start Construction on Final Building in Trophy Adaptive Reuse Project

Retrieved on: 
Thursday, February 17, 2022
JV, Big Cypress National Preserve, Birdseye, Southeastern United States, Tuck, HVAC, Partnership, Acquisition, Abacus, Foot, CBRE, SF, Heart, Commercial property

The lease at 925 Tuckaseegee brings the first of the two innovative and highly design-oriented buildings to 75% leased.

Key Points: 
  • The lease at 925 Tuckaseegee brings the first of the two innovative and highly design-oriented buildings to 75% leased.
  • The partnership also announced the start of construction on the second and final phase of the Switch Yard, a complementary, adjacent 66,000 square foot adaptive reuse trophy office building branded 1001 Tuck.
  • "Abacus and its partners are ecstatic to welcome Birdseye Renewable Energy, a leader in renewable energy development throughout the Southeast, to 925 Tuck at the Switch Yard," said Wes McAdams, managing partner of Abacus Capital.
  • Abacus' mission is to identify investment opportunities that we believe offer our investors the most compelling risk-adjusted returns in dynamic capital markets environments.

FCP, ABACUS CAPITAL AND BIG CYPRESS CAPITAL ANNOUNCE 11,850 SF CLANCY & THEYS LEASE; CONSTRUCTION STARTS FOR THE QUARTER SOUTH END

Retrieved on: 
Thursday, December 16, 2021
Organization, Conor Brennan, Foundry, Solution, JLL, Quarter, South Lanarkshire, Growth, NYSE, Creativity, JV, Big Cypress National Preserve, Time, Acquisition, R, Investment, Southeastern United States, Quarter, MD, Sun Belt, JLL (company), Technology, FCP, Video game, Self storage, Property management, Commercial property, Abacus

CHEVY CHASE, Md., Dec. 16, 2021 /PRNewswire/ --FCP, with JV partners Abacus Capital (Abacus) and Big Cypress Capital (Big Cypress), has signed Clancy & Theys Construction Company to an 11,850-square-foot lease, relocating its Charlotte office to 22EIGHTEEN Toomey, a 24,252-square-foot adaptive reuse office building within The Quarter South End.

Key Points: 
  • CHEVY CHASE, Md., Dec. 16, 2021 /PRNewswire/ --FCP, with JV partners Abacus Capital (Abacus) and Big Cypress Capital (Big Cypress), has signed Clancy & Theys Construction Company to an 11,850-square-foot lease, relocating its Charlotte office to 22EIGHTEEN Toomey, a 24,252-square-foot adaptive reuse office building within The Quarter South End.
  • Clancy & Theys is a family-owned construction company with projects in 19 states including apartments, office buildings, hotels, R&D facilities and more.
  • The Quarter South End adaptive reuse buildings offer tenants a range of available spaces from 5,000 square feet to 77,000 square feet.
  • "Abacus Capital is pleased to partner with Clancy & Theys around their new office location in the Charlotte market," said Wes McAdams, managing partner at Abacus Capital.

SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Monday, November 22, 2021
Research and development, Government, Cancer, SAB, Doctor of Philosophy, United States Department of Defense, COVID-19, Genetic engineering, TC, Aurora, Illinois shooting, Nasdaq, Twitter, Organ transplantation, R, Mutation, GLOBE, Knowledge, Infection, G&A, Immunotherapy, Licensure, Administration, Big Cypress National Preserve, Growth, Vaccine, Pharmaceutical industry

SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) --  SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.
  • The business combination, which closed in October 2021, resulted in gross proceeds to SAB of approximately $30 million.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Retrieved on: 
Monday, October 25, 2021
Science, LLP, Research, Immunotherapy, Technology, Lazard, Entrepreneurship, Cancer, Delta, TC, Ladenburg Thalmann, NIH, Twitter, Organ transplantation, SPAC, NASDAQ, FDA, Government, Infection, Genetic engineering, Stradling Yocca Carlson & Rauth, Nasdaq, Intention, Board, COVID-19, BCYP, M&A, Executive, Acquisition, GLOBE, SAB, Business architecture, Director, Big Cypress National Preserve, Fine chemical, Vaccine, Pharmaceutical industry

SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (Nasdaq: BCYP) (“Big Cypress”), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical firms. The common stock and warrants of the resulting combined company, SAB Biotherapeutics Inc. will commence trading on the Nasdaq Global Market (the “NASDAQ”) under the ticker symbol “SABS” and “SABSW”, respectively, on October 25, 2021.

Key Points: 
  • The common stock and warrants of the resulting combined company, SAB Biotherapeutics Inc. will commence trading on the Nasdaq Global Market (the NASDAQ) under the ticker symbol SABS and SABSW, respectively, on October 25, 2021.
  • The SAB team is committed to progressing our science and expanding the reach of our unique DiversitAb platform, now as a public company.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

Retrieved on: 
Thursday, October 21, 2021
Registration statement, Immunotherapy, Securities Act of 1933, Lists of diseases, Cancer, Industry, TC, Name, Combination company, Twitter, Security (finance), Organ transplantation, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, Big Cypress National Preserve, Infection, Antibody, SEC, Probability, Government, Communication, Review, Genetic engineering, Forward-looking statement, CEO, COVID-19, Growth, BCYP, Special, Prospectus, Acquisition, Therapy, Proxy, SAB, Business, Nasdaq, Doctor of Philosophy, Business architecture, Cypress, Register, Sale, Management

Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.

Key Points: 
  • Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.
  • On October 20, 2021, the stockholders of Big Cypress voted in favor of a proposal to approve the Business Combination at the special meeting of stockholders.
  • Investors and security holders of Big Cypress are advised to read the proxy statement/prospectus in connection with Big Cypress' solicitation of proxies for its special meeting of stockholders to be held to approve the proposed business combination (and related matters) because the proxy statement/prospectus contains important information about the proposed business combination and the parties to the proposed business combination.
  • Big Cypress, SAB and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Big Cypress' stockholders in connection with the proposed business combination.

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Infection, Securities Act of 1933, Probability, Endocrinology, SAB, College, Pediatric endocrinology, Proxy, Johns Hopkins School of Medicine, Sale, Organ transplantation, NASDAQ, Private Securities Litigation Reform Act, Cancer, Webcast, Registration statement, MD, Bloomberg, TC, BCYP, University of Florida, Johns Hopkins Bloomberg School of Public Health, Immunotherapy, Twitter, University, Communication, Immunology, Register, COVID-19, Big Cypress National Preserve, Public health, Genetic engineering, Forward-looking statement, Prospectus, Doctor of Philosophy, Alfred, Government, Name, SEC, Vaccine, Public relations

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m.
  • A replay of the webcast will be available on the SAB website following the event.
  • On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP).
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

Retrieved on: 
Tuesday, September 28, 2021
Oncology, Professional Services, Health, Other Health, Finance, Pharmaceutical, Biotechnology, Hewlett-Packard, Infection, Securities Act of 1933, Probability, DSMB, SAB, AstraZeneca, Therapy, Proxy, Sale, World Fuel Services, Organ transplantation, Private Securities Litigation Reform Act, Cancer, Multimedia, Registration statement, Teva Pharmaceuticals, TC, Teva, Business, Immunotherapy, Twitter, CEO, University, Communication, St. Lawrence University, Clorox, Register, COVID-19, Technology, Aurora, Illinois shooting, Big Cypress National Preserve, Genetic engineering, MBA, CFO, HBO, NIH, Forward-looking statement, Prospectus, Doctor of Philosophy, Government, Name, SEC, Pharmaceutical industry

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021.
  • Mr. Beyer brings more than 25 years of experience to SAB overseeing financial functions at pharmaceutical and other Fortune 100 firms including AstraZeneca, Teva Pharmaceuticals and HBO.
  • Mr. Beyer began his career at the Hewlett-Packard Company, where he ultimately served as a country chief financial officer.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, BCYP, Form, CDC, Immunotherapy, Government, SAB, Private Securities Litigation Reform Act, Forward-looking statement, A type, Prospectus, Genetic engineering, Doctor of Philosophy, Patient, Proxy, Viral load, Register, Securities Act of 1933, Risk, Influenza, Big Cypress National Preserve, Use-centered design, Probability, Safety, Infection, Vaccine, NASDAQ, Communication, TC, COVID-19, Twitter, Name, Population, Real-time, Registration statement, SEC, Organ transplantation, Sale, Cancer, SAB-176, Seasonal Influenza, SAB Biotherapeutics, Inc., SAB-176, SEASONAL INFLUENZA, SAB BIOTHERAPEUTICS, INC.

SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.

Key Points: 
  • SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.
  • The Phase 2a clinical trial is a randomized, double-blind, placebo-controlled study that is evaluating the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza virus strain (pH1N1).
  • SAB-176 is also currently being evaluated in a Phase 1 ascending dose, double-blind, randomized, placebo-controlled safety trial in healthy volunteers, which has also completed enrollment.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.